U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Advanced Pleural Malignant Mesothelioma

MedGen UID:
208925
•Concept ID:
C0854889
•
Neoplastic Process
Synonyms: Advanced Malignant Mesothelioma of Pleura; Advanced Malignant Mesothelioma of the Pleura; Malignant Pleural Mesothelioma, Advanced

Definition

Malignant mesothelioma that arises from the pleura and is classified as stage II, stage III, or stage IV. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVAdvanced Pleural Malignant Mesothelioma

Professional guidelines

PubMed

Treatment patterns and outcomes in older patients with advanced malignant pleural mesothelioma: Analyses of Surveillance, Epidemiology, and End Results-Medicare data.
Danese MD, Daumont M, Nwokeji E, Gleeson M, Penrod JR, Lubeck D
Cancer Rep (Hoboken) 2022 Sep;5(9):e1568. Epub 2021 Oct 26 doi: 10.1002/cnr2.1568. PMID: 34698447Free PMC Article
Treatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting.
Waterhouse DM, Nwokeji ED, Boyd M, Penrod JR, Espirito JL, Robert NJ, Daumont MJ
Future Oncol 2021 Jul;17(19):2439-2448. Epub 2021 Mar 26 doi: 10.2217/fon-2021-0047. PMID: 33769073
A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma.
Petrelli F, Ardito R, Conti B, Coinu A, Cabiddu M, Ghilardi M, Borgonovo K, Barni S, Ghidini A
Respir Med 2018 Aug;141:72-80. Epub 2018 Jun 30 doi: 10.1016/j.rmed.2018.06.026. PMID: 30053976

Recent clinical studies

Etiology

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.
Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, Grosso F, Lo Russo G, Florescu M, Mencoboni M, Morabito A, Cecere FL, Ceresoli GL, Dawe DE, Zucali PA, Pagano M, Goffin JR, Sanchez ML, Gridelli C, Zalcman G, Quantin X, Westeel V, Gargiulo P, Delfanti S, Tu D, Lee CW, Leighl N, Sederias J, Brown-Walker P, Luo Y, Lantuejoul S, Tsao MS, Scherpereel A, Bradbury P, Laurie SA, Seymour L
Lancet 2023 Dec 16;402(10419):2295-2306. Epub 2023 Nov 3 doi: 10.1016/S0140-6736(23)01613-6. PMID: 37931632
Asbestos-associated pulmonary disease.
Caceres JD, Venkata AN
Curr Opin Pulm Med 2023 Mar 1;29(2):76-82. Epub 2023 Jan 11 doi: 10.1097/MCP.0000000000000939. PMID: 36630203
Management of Advanced Pleural Mesothelioma-At the Crossroads.
Nowak AK, Jackson A, Sidhu C
JCO Oncol Pract 2022 Feb;18(2):116-124. Epub 2021 Sep 7 doi: 10.1200/OP.21.00426. PMID: 34491782
Fibulin-3 as biomarker of malignant mesothelioma.
Ledda C, Caltabiano R, Vella F, Matera S, Marconi A, Loreto C, Rapisarda V
Biomark Med 2019 Jul;13(10):875-886. Epub 2019 Jun 25 doi: 10.2217/bmm-2018-0285. PMID: 31237454
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT)
Lancet 2016 Apr 2;387(10026):1405-1414. Epub 2015 Dec 21 doi: 10.1016/S0140-6736(15)01238-6. PMID: 26719230

Diagnosis

The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification.
Sauter JL, Dacic S, Galateau-Salle F, Attanoos RL, Butnor KJ, Churg A, Husain AN, Kadota K, Khoor A, Nicholson AG, Roggli V, Schmitt F, Tsao MS, Travis WD
J Thorac Oncol 2022 May;17(5):608-622. Epub 2022 Jan 10 doi: 10.1016/j.jtho.2021.12.014. PMID: 35026477
Malignant pleural mesothelioma: an update.
Hajj GNM, Cavarson CH, Pinto CAL, Venturi G, Navarro JR, Lima VCC
J Bras Pneumol 2021;47(6):e20210129. Epub 2021 Dec 13 doi: 10.36416/1806-3756/e20210129. PMID: 34909922Free PMC Article
Diagnosis of Mesothelioma.
Fels Elliott DR, Jones KD
Surg Pathol Clin 2020 Mar;13(1):73-89. Epub 2019 Dec 3 doi: 10.1016/j.path.2019.10.001. PMID: 32005436
Advances in pleuroscopy.
Anevlavis S, Froudarakis ME
Clin Respir J 2018 Mar;12(3):839-847. Epub 2017 Jan 11 doi: 10.1111/crj.12597. PMID: 27997741
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT)
Lancet 2016 Apr 2;387(10026):1405-1414. Epub 2015 Dec 21 doi: 10.1016/S0140-6736(15)01238-6. PMID: 26719230

Therapy

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.
Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, Grosso F, Lo Russo G, Florescu M, Mencoboni M, Morabito A, Cecere FL, Ceresoli GL, Dawe DE, Zucali PA, Pagano M, Goffin JR, Sanchez ML, Gridelli C, Zalcman G, Quantin X, Westeel V, Gargiulo P, Delfanti S, Tu D, Lee CW, Leighl N, Sederias J, Brown-Walker P, Luo Y, Lantuejoul S, Tsao MS, Scherpereel A, Bradbury P, Laurie SA, Seymour L
Lancet 2023 Dec 16;402(10419):2295-2306. Epub 2023 Nov 3 doi: 10.1016/S0140-6736(23)01613-6. PMID: 37931632
New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.
Tsao AS, Pass HI, Rimner A, Mansfield AS
J Clin Oncol 2022 Feb 20;40(6):681-692. Epub 2022 Jan 5 doi: 10.1200/JCO.21.01567. PMID: 34985934Free PMC Article
The Molecular Basis of Malignant Pleural Mesothelioma.
Wadowski B, De Rienzo A, Bueno R
Thorac Surg Clin 2020 Nov;30(4):383-393. Epub 2020 Sep 12 doi: 10.1016/j.thorsurg.2020.08.005. PMID: 33012428Free PMC Article
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT)
Lancet 2016 Apr 2;387(10026):1405-1414. Epub 2015 Dec 21 doi: 10.1016/S0140-6736(15)01238-6. PMID: 26719230
Malignant pleural mesothelioma.
Raja S, Murthy SC, Mason DP
Curr Oncol Rep 2011 Aug;13(4):259-64. doi: 10.1007/s11912-011-0177-9. PMID: 21573909

Prognosis

The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification.
Sauter JL, Dacic S, Galateau-Salle F, Attanoos RL, Butnor KJ, Churg A, Husain AN, Kadota K, Khoor A, Nicholson AG, Roggli V, Schmitt F, Tsao MS, Travis WD
J Thorac Oncol 2022 May;17(5):608-622. Epub 2022 Jan 10 doi: 10.1016/j.jtho.2021.12.014. PMID: 35026477
New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.
Tsao AS, Pass HI, Rimner A, Mansfield AS
J Clin Oncol 2022 Feb 20;40(6):681-692. Epub 2022 Jan 5 doi: 10.1200/JCO.21.01567. PMID: 34985934Free PMC Article
Malignant Pleural Effusion and Its Current Management: A Review.
Skok K, Hladnik G, Grm A, Crnjac A
Medicina (Kaunas) 2019 Aug 15;55(8) doi: 10.3390/medicina55080490. PMID: 31443309Free PMC Article
Advances in pleuroscopy.
Anevlavis S, Froudarakis ME
Clin Respir J 2018 Mar;12(3):839-847. Epub 2017 Jan 11 doi: 10.1111/crj.12597. PMID: 27997741
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT)
Lancet 2016 Apr 2;387(10026):1405-1414. Epub 2015 Dec 21 doi: 10.1016/S0140-6736(15)01238-6. PMID: 26719230

Clinical prediction guides

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.
Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, Grosso F, Lo Russo G, Florescu M, Mencoboni M, Morabito A, Cecere FL, Ceresoli GL, Dawe DE, Zucali PA, Pagano M, Goffin JR, Sanchez ML, Gridelli C, Zalcman G, Quantin X, Westeel V, Gargiulo P, Delfanti S, Tu D, Lee CW, Leighl N, Sederias J, Brown-Walker P, Luo Y, Lantuejoul S, Tsao MS, Scherpereel A, Bradbury P, Laurie SA, Seymour L
Lancet 2023 Dec 16;402(10419):2295-2306. Epub 2023 Nov 3 doi: 10.1016/S0140-6736(23)01613-6. PMID: 37931632
New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.
Tsao AS, Pass HI, Rimner A, Mansfield AS
J Clin Oncol 2022 Feb 20;40(6):681-692. Epub 2022 Jan 5 doi: 10.1200/JCO.21.01567. PMID: 34985934Free PMC Article
Malignant Pleural Effusion and Its Current Management: A Review.
Skok K, Hladnik G, Grm A, Crnjac A
Medicina (Kaunas) 2019 Aug 15;55(8) doi: 10.3390/medicina55080490. PMID: 31443309Free PMC Article
Advances in pleuroscopy.
Anevlavis S, Froudarakis ME
Clin Respir J 2018 Mar;12(3):839-847. Epub 2017 Jan 11 doi: 10.1111/crj.12597. PMID: 27997741
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT)
Lancet 2016 Apr 2;387(10026):1405-1414. Epub 2015 Dec 21 doi: 10.1016/S0140-6736(15)01238-6. PMID: 26719230

Recent systematic reviews

DNA Methylation as a Diagnostic Biomarker for Malignant Mesothelioma: A Systematic Review and Meta-Analysis.
Vandenhoeck J, van Meerbeeck JP, Fransen E, Raskin J, Van Camp G, Op de Beeck K, Lamote K
J Thorac Oncol 2021 Sep;16(9):1461-1478. Epub 2021 May 31 doi: 10.1016/j.jtho.2021.05.015. PMID: 34082107
A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma.
Petrelli F, Ardito R, Conti B, Coinu A, Cabiddu M, Ghilardi M, Borgonovo K, Barni S, Ghidini A
Respir Med 2018 Aug;141:72-80. Epub 2018 Jun 30 doi: 10.1016/j.rmed.2018.06.026. PMID: 30053976
Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review.
Abdel-Rahman O, Kelany M
Expert Rev Respir Med 2015 Oct;9(5):533-49. Epub 2015 Sep 7 doi: 10.1586/17476348.2015.1083426. PMID: 26366804
Randomized Trials of Systemic Medically-treated Malignant Mesothelioma: A Systematic Review.
Blomberg C, Nilsson J, Holgersson G, Edlund P, Bergqvist M, Adwall L, Ekman S, Brattström D, Bergström S
Anticancer Res 2015 May;35(5):2493-501. PMID: 25964522
Radiotherapy for malignant pleural mesothelioma.
Chapman E, Berenstein EG, Diéguez M, Ortiz Z
Cochrane Database Syst Rev 2006 Jul 19;2006(3):CD003880. doi: 10.1002/14651858.CD003880.pub4. PMID: 16856023Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...